Test BankFor Clayton’s Basic Pharmacology forNurses 19thE ditionB y
m
f fm m
f m
f mf m
f fm m
f m
f lw mf mf
Michelle J. Willihnganz, Samuel L. Gurevitz, Bruce Clayton Compl ete
mf mf mf mf mf mf mf mf mf
, Chapter 01: Drug Definitions, Standards, and Information Sources Willihnga n
mf mf mf mf mf mf mf mf mf
z: Clayton’s Basic Pharmacology for Nurses, 19th Edition
mf mf mf m f mf mf mf
MULTIPLE CHOICE
1. Which name identifies a drug listed by the US Food a
nd Drug Administration (FDA)?
lw
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS: C
The official name is the name under which a drug is liste
d by the FDA. The brand name, or trademark, is the name
given to a drug by its manufacturer. The nonproprietary,
or generic, name is provided by the United States Adopted
Names Council.
DIF: Cognitive Level: Knowledge REF: p. 9 mf mf m f m f
OBJ: 1NAT: NCLEX Client Needs Category: Safe, Effective C
mf mf mf mf mf mf mf mf mf
are Environment TOP: Nursing Process Step: Assessment
lw mf mf mf mf
CON:
Patient Education m f
2. Which source contains information specific to nutritional supplements?
mf mf mf mf mf mf mf
a. USP Dictionary of USAN &International Drug Names
mf mf mf m f mf mf
b. Natural Medicines Comprehensive Database mf mf mf
c. United States Pharmacopoeia/National Formulary (USP NF)
mf mf mf mf mf
d. Drug Interaction Facts mf mf
ANS: C m f
United States Pharmacopoeia/National Formulary contains information specific t o nutritiona
mf mf mf mf mf mf mf mf mf
l supplements. USP Dictionary of USAN & International Drug Names is a compilation of d r
w mf mf mf mf mf mf mf mf mf mf mf mf mf mf
ug names, pronunciation guide, and possible future FDA approved drugs; it does not inclu d
lw mf mf mf mf mf mf mf mf mf mf mf mf mf
e nutritional supplements. Natural Medicines Comprehensive Database contains
mf mf mf mf mf mf mf
evidence-
ducts; it does not include i
mf mf mf w mf
nformation specific to nutritional supplements. Drug Interaction Facts contains comprehen
mf mf mf mf mf mf mf mf mf
sive information on drug interaction facts; it does not include nutritional supplement
mf m f mf mf m f m f m f m f mf m f m f m f
s.
DIF: Cognitive Level: Knowledge REF: p. 4 mf mf mf
OBJ: 3 NAT: NCLEX Client Needs Category: Physiological Int
mf lw m f mf mf mf mf mf
egrity
TOP: Nursing Process Step: Assessment CON: Nutrition | Patient Education
wl mf mf m f m f m f mf mf
3. Which drug reference contains drug monographs that describe all drugs in a therapeutic class?
mf mf mf mf wl mf mf mf mf mf mf mf mf
a. Drug Facts and Comparisons mf mf mf
,Test Bank For Clayton’s Basic Pharmacology for Nurses 19th Editi wl 3
b. Drug Interaction Facts mf mf
c. Handbook on Injectable Drugs mf mf mf
d. Martindale—The Complete Drug Reference mf mf mf
ANS: A m f
Drug Facts and Comparisons contains drug monographs that describe all drugs in a
mf mf mf mf mf mf mf mf mf mf mf mf lw
therapeutic class. Monographs are formatted as t ables t o allow comparison of simil ar
mf mf mf mf mf mf mf mf mf mf mf mf
products, brand names, manufacturers, cost indices, and available dosage forms Onli
mf mf mf mf mf mf mf mf mf mf
ne version is available.
mf mf mf
DIF: Cognitive Level: Knowledge REF: p. 4 Table 1.2 mf mf m f m f m f mf mf
OBJ: 3 NAT: NCLEX Client Needs Category: Physiological Integrity m f mf mf mf mf mf
TOP: Nursing Process Step: Assessment CON: Safety | Patient Education | Clinical Judgment
wl mf mf m f m f mf mf m f mf mf mf
4. Which drug reference contains monographs about virtually every s ingle-
mf mf mf m f mf m f mf m
f
entitydrug available in the United States and describes therapeutic uses of drugs, includin
mf lw mf mf mf mf mf mf mf mf mf mf
g approved and unapproved uses?
m f mf mf mf mf
a. Martindale: The Complete Drug Reference mf mf mf mf
b. AHFS Drug Information mf mf
c. Drug Reference mf
d. Drug Facts and Comparisons mf mf mf
ANS: B m f
AHFS Drug Information contains monographs about virtually every single-
mf mf mf mf mf mf mf m f
entity drug available in the United States and describes therapeutic uses of d rugs, includin
mf mf mf mf mf mf mf mf mf mf mf mf m f
g approved and unapproved uses.
mf mf lw mf
DIF: Cognitive Level: Knowledge REF: p. 4 Table 1.2 mf mf m f m f m f mf mf
OBJ: 3 NAT: NCLEX Client Needs Category: Physiological Integrity m f mf mf mf mf mf
TOP: Nursing Process Step: Planning CON: Safety | Patient Education | Clinical Judgment
mf mf mf m f mf mf m f mf mf mf
5. Which online drug reference makes available to healthcare providers and the public a s
mf mf mf mf mf mf mf mf mf mf mf mf mf m f
tandard, comprehensive, up-to-date look up and downloadable resource about medicines?
mf mf mf mf mf mf mf mf mf
a. American Drug Index mf mf
b. American Hospital Formulary mf mf
c. DailyMed
d. Drug Reference mf
ANS: C m f
DailyMed makes available to healthcare providers and the public a standard, comprehensiv
mf mf mf mf mf mf mf mf mf mf mf m
e, u p - to-
f l w
date look up and downloadable resource about medicines. The American Drug Index is not
mf mf mf mf mf mf mf mf mf mf mf mf lw
appropriate for patient use. The American Hospital Formulary is not appropriate for patie
mf mf mf mf mf mf mf mf mf mf mf mf mf
nt use. The drug reference is not appropriate for patient use.
m f m f m f m f mf m f m f m f m f mf m f
DIF: Cognitive Level: Knowledge REF: p. 3 | p. 4 mf mf mf m f mf m f
OBJ: 3 NAT: NCLEX Client Needs Category: Physiological Int
mf lw m f mf mf mf mf mf
egrity
TOP: Nursing Process Step: Implementation
m f mf mf mf
CON: Safety | Patient Education | Clinical Judgment
m f mf mf mf m f mf mf
6. Which legislation authorizes the FDA to determine the safetyof a drug before its marketing?
mf mf mf mf mf mf mf mf mf mf mf mf mf
a. Federal Food, Drug, and Cosmetic Act (1938) mf mf mf mf mf mf
b. Durham Humphrey Amendment (1952) mf mf m f
, Test Bank For Clayton’s Basic Pharmacology for Nurses 19th Editi wl 4
c. Controlled Substances Act (1970) mf mf mf
d. Kefauver Harris Drug Amendment (1962) mf mf mf mf
ANS: A m f
The Federal Food, Drug, and Cosmetic Act of 1938 authorized the FDA to determine the s
mf mf mf mf mf mf mf mf mf mf mf mf mf mf mf m
fafety of all drugs before marketing. Later amendments and acts helped tighten FDA c
mf mf mf mf mf mf m f m f mf m f m f mf mf
ontro l and ensure drug safety. The Durham Humphrey Amendment defines the kinds of dru
mf mf mf mf mf mf mf mf mf mf mf mf mf mf
gs t hat cannot be used safely without medical supervision and restricts their sale to
mf m f m f mf mf mf mf mf m f m f m f mf m f mf m f
prescriptio n by a licensed practitioner. The Controlled Substances Act addresses only contr
mf mf mf mf mf mf mf mf mf mf mf mf
olled subst ances and their categorization. The Kefauver Harris Drug Amendment ensures dr
mf mf mf lw mf mf mf mf mf mf mf mf
ug efficacy and greater drug safety. Drug manufacturers are required to prove to the FDA th
mf mf mf lw mf mf mf mf mf mf mf mf mf mf mf
e effective ness of their products before marketing them.
mf mf mf mf mf mf mf mf
DIF: Cognitive Level: Knowledge mf mf
REF: p. 5 Table l.3 OBJ: 5 mf m f mf mf mf
NAT: NCLEX Client Needs Category: Physiological Integrit y mf mf mf mf mf mf mf lw
TOP: Nursing Process Step: Assessment
m f mf m f mf
CON: Safety | Patient Education | Evidence | Health Care Law
m f m f mf m f m f mf m f mf mf mf
7. Which classification does meperidine (Demerol) fall under?
mf mf mf mf m f mf
a. I
b. II
c. III
d. IV
ANS: B m f
Meperidine (Demerol) is a Schedule II drug; it has a high potential for abuse and ma
m f mf m f m f m f mf m f m f m f mf m f m f m f m f m f
y lea d to severe psychological and physical dependence. Schedule I d rugs have high potenti
mf mf mf lw mf mf mf mf mf mf mf mf mf mf
al for abuse and no recognized medical use. Schedule III drugs have some potential for abu
mf mf lw mf mf mf mf mf mf mf mf mf mf mf mf
se. Us e may lead to low to moderate physical dependence or high psychological depende
mf m f mf mf mf mf mf mf mf mf mf mf mf mf
nce. Sc hedule IVdrugs have low potential for abuse. Use may lead to limited physical or p
mf m f mf mf mf mf mf mf mf mf mf mf mf mf mf mf
sychol ogical dependence. m f mf
DIF: Cognitive Level: Knowledge REF: p. 10 mf mf mf
OBJ: 2 NAT: NCLEX Client Needs Category: Safe, Effective mf lw m f mf mf mf mf mf mf
C are Environment
mf mf
TOP: Nursing Process Step: Assessment CON: Patient Education | Addiction | Pain mf mf mf m f m f m f m f mf mf mf
8. Which action would the FDA t ake to expedite drug d evelopment and approval for an outbre
mf mf mf mf mf mf mf mf mf m f mf mf mf mf
mf ak of smallpox?
lw mf
a. List smallpox as a health orphan d isease.
mf mf mf mf mf mf
b. Omit the preclinical research phase. mf mf mf mf
c. Extend the clinical research phase. mf mf mf mf
d. Fast track the investigational d rug. mf mf mf mf
ANS: D m f
Once the Investigational New Drug Application has been approved, the drug can receive h i
mf mf mf mf mf mf mf mf mf mf mf mf mf m f
ghest priority within the agency, which is called fast tracking. A smallpox outbreak would b
mf mf mf mf mf mf mf mf mf mf mf mf mf m f
ecome a priority concern in the world. Orphan diseases are not researched in a priority ma
mf mf mf mf mf mf mf mf mf mf mf mf mf mf m f
nner. Preclinical research is not omitted. Extending any phase of the research would me an
mf mf mf mf mf mf mf mf mf mf mf mf mf m f lw
a longer time to develop a vaccine. The FDA must ensure t hat all phases of the preclinical an
mf mf mf mf mf mf mf mf mf mf mf mf mf mf mf mf mf
d clinical research phase have been completed in a safe manner.
lw mf mf mf mf mf mf mf mf mf
DIF: Cognitive Level: Knowledge mf mf REF: p. 7 mf OBJ: 5 m f
m
f fm m
f m
f mf m
f fm m
f m
f lw mf mf
Michelle J. Willihnganz, Samuel L. Gurevitz, Bruce Clayton Compl ete
mf mf mf mf mf mf mf mf mf
, Chapter 01: Drug Definitions, Standards, and Information Sources Willihnga n
mf mf mf mf mf mf mf mf mf
z: Clayton’s Basic Pharmacology for Nurses, 19th Edition
mf mf mf m f mf mf mf
MULTIPLE CHOICE
1. Which name identifies a drug listed by the US Food a
nd Drug Administration (FDA)?
lw
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS: C
The official name is the name under which a drug is liste
d by the FDA. The brand name, or trademark, is the name
given to a drug by its manufacturer. The nonproprietary,
or generic, name is provided by the United States Adopted
Names Council.
DIF: Cognitive Level: Knowledge REF: p. 9 mf mf m f m f
OBJ: 1NAT: NCLEX Client Needs Category: Safe, Effective C
mf mf mf mf mf mf mf mf mf
are Environment TOP: Nursing Process Step: Assessment
lw mf mf mf mf
CON:
Patient Education m f
2. Which source contains information specific to nutritional supplements?
mf mf mf mf mf mf mf
a. USP Dictionary of USAN &International Drug Names
mf mf mf m f mf mf
b. Natural Medicines Comprehensive Database mf mf mf
c. United States Pharmacopoeia/National Formulary (USP NF)
mf mf mf mf mf
d. Drug Interaction Facts mf mf
ANS: C m f
United States Pharmacopoeia/National Formulary contains information specific t o nutritiona
mf mf mf mf mf mf mf mf mf
l supplements. USP Dictionary of USAN & International Drug Names is a compilation of d r
w mf mf mf mf mf mf mf mf mf mf mf mf mf mf
ug names, pronunciation guide, and possible future FDA approved drugs; it does not inclu d
lw mf mf mf mf mf mf mf mf mf mf mf mf mf
e nutritional supplements. Natural Medicines Comprehensive Database contains
mf mf mf mf mf mf mf
evidence-
ducts; it does not include i
mf mf mf w mf
nformation specific to nutritional supplements. Drug Interaction Facts contains comprehen
mf mf mf mf mf mf mf mf mf
sive information on drug interaction facts; it does not include nutritional supplement
mf m f mf mf m f m f m f m f mf m f m f m f
s.
DIF: Cognitive Level: Knowledge REF: p. 4 mf mf mf
OBJ: 3 NAT: NCLEX Client Needs Category: Physiological Int
mf lw m f mf mf mf mf mf
egrity
TOP: Nursing Process Step: Assessment CON: Nutrition | Patient Education
wl mf mf m f m f m f mf mf
3. Which drug reference contains drug monographs that describe all drugs in a therapeutic class?
mf mf mf mf wl mf mf mf mf mf mf mf mf
a. Drug Facts and Comparisons mf mf mf
,Test Bank For Clayton’s Basic Pharmacology for Nurses 19th Editi wl 3
b. Drug Interaction Facts mf mf
c. Handbook on Injectable Drugs mf mf mf
d. Martindale—The Complete Drug Reference mf mf mf
ANS: A m f
Drug Facts and Comparisons contains drug monographs that describe all drugs in a
mf mf mf mf mf mf mf mf mf mf mf mf lw
therapeutic class. Monographs are formatted as t ables t o allow comparison of simil ar
mf mf mf mf mf mf mf mf mf mf mf mf
products, brand names, manufacturers, cost indices, and available dosage forms Onli
mf mf mf mf mf mf mf mf mf mf
ne version is available.
mf mf mf
DIF: Cognitive Level: Knowledge REF: p. 4 Table 1.2 mf mf m f m f m f mf mf
OBJ: 3 NAT: NCLEX Client Needs Category: Physiological Integrity m f mf mf mf mf mf
TOP: Nursing Process Step: Assessment CON: Safety | Patient Education | Clinical Judgment
wl mf mf m f m f mf mf m f mf mf mf
4. Which drug reference contains monographs about virtually every s ingle-
mf mf mf m f mf m f mf m
f
entitydrug available in the United States and describes therapeutic uses of drugs, includin
mf lw mf mf mf mf mf mf mf mf mf mf
g approved and unapproved uses?
m f mf mf mf mf
a. Martindale: The Complete Drug Reference mf mf mf mf
b. AHFS Drug Information mf mf
c. Drug Reference mf
d. Drug Facts and Comparisons mf mf mf
ANS: B m f
AHFS Drug Information contains monographs about virtually every single-
mf mf mf mf mf mf mf m f
entity drug available in the United States and describes therapeutic uses of d rugs, includin
mf mf mf mf mf mf mf mf mf mf mf mf m f
g approved and unapproved uses.
mf mf lw mf
DIF: Cognitive Level: Knowledge REF: p. 4 Table 1.2 mf mf m f m f m f mf mf
OBJ: 3 NAT: NCLEX Client Needs Category: Physiological Integrity m f mf mf mf mf mf
TOP: Nursing Process Step: Planning CON: Safety | Patient Education | Clinical Judgment
mf mf mf m f mf mf m f mf mf mf
5. Which online drug reference makes available to healthcare providers and the public a s
mf mf mf mf mf mf mf mf mf mf mf mf mf m f
tandard, comprehensive, up-to-date look up and downloadable resource about medicines?
mf mf mf mf mf mf mf mf mf
a. American Drug Index mf mf
b. American Hospital Formulary mf mf
c. DailyMed
d. Drug Reference mf
ANS: C m f
DailyMed makes available to healthcare providers and the public a standard, comprehensiv
mf mf mf mf mf mf mf mf mf mf mf m
e, u p - to-
f l w
date look up and downloadable resource about medicines. The American Drug Index is not
mf mf mf mf mf mf mf mf mf mf mf mf lw
appropriate for patient use. The American Hospital Formulary is not appropriate for patie
mf mf mf mf mf mf mf mf mf mf mf mf mf
nt use. The drug reference is not appropriate for patient use.
m f m f m f m f mf m f m f m f m f mf m f
DIF: Cognitive Level: Knowledge REF: p. 3 | p. 4 mf mf mf m f mf m f
OBJ: 3 NAT: NCLEX Client Needs Category: Physiological Int
mf lw m f mf mf mf mf mf
egrity
TOP: Nursing Process Step: Implementation
m f mf mf mf
CON: Safety | Patient Education | Clinical Judgment
m f mf mf mf m f mf mf
6. Which legislation authorizes the FDA to determine the safetyof a drug before its marketing?
mf mf mf mf mf mf mf mf mf mf mf mf mf
a. Federal Food, Drug, and Cosmetic Act (1938) mf mf mf mf mf mf
b. Durham Humphrey Amendment (1952) mf mf m f
, Test Bank For Clayton’s Basic Pharmacology for Nurses 19th Editi wl 4
c. Controlled Substances Act (1970) mf mf mf
d. Kefauver Harris Drug Amendment (1962) mf mf mf mf
ANS: A m f
The Federal Food, Drug, and Cosmetic Act of 1938 authorized the FDA to determine the s
mf mf mf mf mf mf mf mf mf mf mf mf mf mf mf m
fafety of all drugs before marketing. Later amendments and acts helped tighten FDA c
mf mf mf mf mf mf m f m f mf m f m f mf mf
ontro l and ensure drug safety. The Durham Humphrey Amendment defines the kinds of dru
mf mf mf mf mf mf mf mf mf mf mf mf mf mf
gs t hat cannot be used safely without medical supervision and restricts their sale to
mf m f m f mf mf mf mf mf m f m f m f mf m f mf m f
prescriptio n by a licensed practitioner. The Controlled Substances Act addresses only contr
mf mf mf mf mf mf mf mf mf mf mf mf
olled subst ances and their categorization. The Kefauver Harris Drug Amendment ensures dr
mf mf mf lw mf mf mf mf mf mf mf mf
ug efficacy and greater drug safety. Drug manufacturers are required to prove to the FDA th
mf mf mf lw mf mf mf mf mf mf mf mf mf mf mf
e effective ness of their products before marketing them.
mf mf mf mf mf mf mf mf
DIF: Cognitive Level: Knowledge mf mf
REF: p. 5 Table l.3 OBJ: 5 mf m f mf mf mf
NAT: NCLEX Client Needs Category: Physiological Integrit y mf mf mf mf mf mf mf lw
TOP: Nursing Process Step: Assessment
m f mf m f mf
CON: Safety | Patient Education | Evidence | Health Care Law
m f m f mf m f m f mf m f mf mf mf
7. Which classification does meperidine (Demerol) fall under?
mf mf mf mf m f mf
a. I
b. II
c. III
d. IV
ANS: B m f
Meperidine (Demerol) is a Schedule II drug; it has a high potential for abuse and ma
m f mf m f m f m f mf m f m f m f mf m f m f m f m f m f
y lea d to severe psychological and physical dependence. Schedule I d rugs have high potenti
mf mf mf lw mf mf mf mf mf mf mf mf mf mf
al for abuse and no recognized medical use. Schedule III drugs have some potential for abu
mf mf lw mf mf mf mf mf mf mf mf mf mf mf mf
se. Us e may lead to low to moderate physical dependence or high psychological depende
mf m f mf mf mf mf mf mf mf mf mf mf mf mf
nce. Sc hedule IVdrugs have low potential for abuse. Use may lead to limited physical or p
mf m f mf mf mf mf mf mf mf mf mf mf mf mf mf mf
sychol ogical dependence. m f mf
DIF: Cognitive Level: Knowledge REF: p. 10 mf mf mf
OBJ: 2 NAT: NCLEX Client Needs Category: Safe, Effective mf lw m f mf mf mf mf mf mf
C are Environment
mf mf
TOP: Nursing Process Step: Assessment CON: Patient Education | Addiction | Pain mf mf mf m f m f m f m f mf mf mf
8. Which action would the FDA t ake to expedite drug d evelopment and approval for an outbre
mf mf mf mf mf mf mf mf mf m f mf mf mf mf
mf ak of smallpox?
lw mf
a. List smallpox as a health orphan d isease.
mf mf mf mf mf mf
b. Omit the preclinical research phase. mf mf mf mf
c. Extend the clinical research phase. mf mf mf mf
d. Fast track the investigational d rug. mf mf mf mf
ANS: D m f
Once the Investigational New Drug Application has been approved, the drug can receive h i
mf mf mf mf mf mf mf mf mf mf mf mf mf m f
ghest priority within the agency, which is called fast tracking. A smallpox outbreak would b
mf mf mf mf mf mf mf mf mf mf mf mf mf m f
ecome a priority concern in the world. Orphan diseases are not researched in a priority ma
mf mf mf mf mf mf mf mf mf mf mf mf mf mf m f
nner. Preclinical research is not omitted. Extending any phase of the research would me an
mf mf mf mf mf mf mf mf mf mf mf mf mf m f lw
a longer time to develop a vaccine. The FDA must ensure t hat all phases of the preclinical an
mf mf mf mf mf mf mf mf mf mf mf mf mf mf mf mf mf
d clinical research phase have been completed in a safe manner.
lw mf mf mf mf mf mf mf mf mf
DIF: Cognitive Level: Knowledge mf mf REF: p. 7 mf OBJ: 5 m f
